Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Tucatinib/Trastuzumab Combination Finds a Role in HER2+ mCRC

February 2nd 2023

John H. Strickler, MD, highlights key findings from the MOUNTAINEER trial and addresses the possibility of moving the combination up to the first line setting.

Neoadjuvant Chemo Reduces 2-Year Risk for Residual, Recurrent Disease by 28% in Colon Cancer

February 1st 2023

Six weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy did not increase perioperative morbidity in patients with radiologically staged T3-4, N0-2, M0 colon cancer, according to findings from the international phase 2/3 FOxTROT trial.

Dr. Fakih on Tumor Microenvironment Differences in MSS mCRC

February 1st 2023

Marwan G. Fakih, MD, discusses a comparative analysis of the tumor microenvironment in primary tumors vs metastatic tissue in patients with microsatellite stable metastatic colorectal cancer.

Dr. Hecht on the Investigation of XL092/Atezolizumab in MSS/MSI-L mCRC

February 1st 2023

J. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.

Dr. Hochster on Trastuzumab/Pertuzumab Vs Cetuximab/Irinotecan in HER2-Amplified mCRC

February 1st 2023

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.

Dr. Cohen on the Timing of ctDNA Testing in Resected Stage I-III CRC

January 31st 2023

Stacey A. Cohen, MD, discusses the investigation of the optimal timing to test for circulating tumor DNA to detect minimal residual disease following surgery in patients with stage I to III colorectal cancer.

Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal Adenocarcinoma

January 31st 2023

Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.

Dr. Morris on the Investigation of the Role of ctDNA in Stage II CRC

January 30th 2023

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC

January 27th 2023

Joleen M. Hubbard, MD, discusses key survival data from the phase 1b study of the PolyPEPI1018 vaccine and the impact of these findings on continued investigations of this vaccine in metastatic colorectal cancer.

Dr. George on Long-Term Data on Total Neoadjuvant Therapy in Rectal Cancer

January 26th 2023

Thomas J. George, MD, FACP, discusses long-term data from the phase 2 NRG-GI002 trial of total neoadjuvant therapy in locally advanced rectal cancer.

FDA Receives Premarket Approval Application for Noninvasive CRC Screening Test

January 24th 2023

Geneoscopy has submitted a premarket approval application to the FDA for a noninvasive, stool-based, at-home screening test to detect colorectal cancer and advanced adenomas in average-risk individuals.

Encorafenib Plus Cetuximab and Chemotherapy Demonstrates Safety, Efficacy in BRAF V600E–Mutant mCRC

January 22nd 2023

The addition of mFOLFOX6 or FOLFIRI to the combination of encorafenib and cetuximab elicited encouraging antitumor activity and safety in patients with BRAF V600E-mutant metastatic colorectal cancer.

Patient-specific Marker Tracking Approach May Better Detect MRD in CRC

January 22nd 2023

A novel Burning Rock patient-specific prognostic and potential therapeutic marker tracking approach demonstrated improved sensitivity in detecting circulating tumor DNA and identifying molecular residual disease compared with other approaches in patients with colorectal cancer following surgery.

ctDNA Could Assist in Early Response Assessment in Advanced CRC

January 22nd 2023

Circulating tumor DNA could serve as an ideal biomarker to assess early response in patients with advanced colorectal cancer due to its short half-life compared with other tumor biomarkers, and it could enable the use of adaptive clinical study designs in the future.

FDA Approves Tucatinib Plus Trastuzumab for RAS Wild-type, HER2+ Metastatic Colorectal Cancer

January 19th 2023

The FDA has granted accelerated approval to tucatinib in combination with trastuzumab for adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Dr. Strickler on the FDA Approval of Tucatinib Plus Trastuzumab in mCRC

January 19th 2023

John H. Strickler, MD, discusses the significance of the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer.

Signatera MRD Test Successfully Identifies Patients With CRC Most Likely to Benefit From Adjuvant Chemotherapy

January 19th 2023

The Signatera molecular residual disease test was able to detect patients with stage II to IV colorectal cancer who were at an increased risk for recurrence and predict which patients were most likely to benefit from adjuvant chemotherapy.

Tucatinib Plus Trastuzumab Could Address Need for New Standard of Care in HER2+ Metastatic CRC

January 18th 2023

Tanios S. Bekaii-Saab, MD, FACP, expands on key data reported from the MOUNTAINEER trial, the potential effects of this regimen’s approval on the current treatment landscape, and the continued investigation of this and other targeted approaches in metastatic colorectal cancer.

Neoadjuvant Immunotherapy Elicits Strong Responses in Localized dMMR/MSI-H Colorectal Cancer

January 16th 2023

Neoadjuvant treatment with anti–PD-1 inhibitors induced high rates of complete response and reduced recurrence rates, according to a retrospective analysis of patients with localized mismatch repair-deficient or microsatellite instability–high colorectal cancer.

Dr. Wu on the Current Utility of Targeted Therapy in CRC

January 12th 2023

Christina Wu, MD, discusses key targeted therapies under investigation in patients with colorectal cancer.